Walter Public Investments Inc. Has $10.24 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Walter Public Investments Inc. lowered its position in Zoetis Inc. (NYSE:ZTSFree Report) by 0.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 59,062 shares of the company’s stock after selling 88 shares during the period. Walter Public Investments Inc.’s holdings in Zoetis were worth $10,239,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of ZTS. Hohimer Wealth Management LLC raised its position in Zoetis by 1.2% in the 4th quarter. Hohimer Wealth Management LLC now owns 4,386 shares of the company’s stock valued at $866,000 after purchasing an additional 52 shares during the last quarter. Asset Dedication LLC lifted its position in Zoetis by 4.8% during the 2nd quarter. Asset Dedication LLC now owns 1,174 shares of the company’s stock worth $204,000 after buying an additional 54 shares in the last quarter. Angeles Wealth Management LLC lifted its position in Zoetis by 3.5% during the 4th quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock worth $324,000 after buying an additional 56 shares in the last quarter. Forza Wealth Management LLC increased its position in Zoetis by 1.8% in the 2nd quarter. Forza Wealth Management LLC now owns 3,313 shares of the company’s stock valued at $574,000 after acquiring an additional 58 shares in the last quarter. Finally, L. Roy Papp & Associates LLP increased its position in Zoetis by 2.8% in the 2nd quarter. L. Roy Papp & Associates LLP now owns 2,221 shares of the company’s stock valued at $385,000 after acquiring an additional 60 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ZTS has been the topic of several research analyst reports. Stifel Nicolaus reissued a “buy” rating and set a $200.00 price target on shares of Zoetis in a research note on Tuesday, August 27th. Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. BTIG Research boosted their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, Piper Sandler raised their price target on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $217.11.

View Our Latest Report on Zoetis

Zoetis Trading Up 0.2 %

NYSE ZTS opened at $191.09 on Monday. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The stock has a 50-day simple moving average of $182.85 and a 200 day simple moving average of $174.14. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The company has a market capitalization of $86.57 billion, a PE ratio of 36.82, a P/E/G ratio of 2.92 and a beta of 0.88.

Zoetis (NYSE:ZTSGet Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. During the same period in the prior year, the business posted $1.41 EPS. Zoetis’s revenue was up 8.3% on a year-over-year basis. Research analysts forecast that Zoetis Inc. will post 5.84 EPS for the current year.

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

See Also

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.